Ann: Immutep to announce new TACTI-002 data at ASCO 2022, page-47

seems like excellent results. Let’s see what announcement pops before open and how well the market interprets it

At data cut-off (Jan 2022), 75 pts with a minimum follow-up of 6 months were evaluated for efficacy. ORR (iRECIST) was 37.3% in the ITT and 41.8%% in the evaluable pts assessed by local read. DCR 73.3% was reported. Response rate for squamous and non-squamous pathology were 33.3 % and 40.3 %, respectively. Results according to RECIST 1.1 were comparable. Responses were observed in all PD-L1 subgroups (Table). 24/28 (86%) responses were already confirmed while median duration of response was not yet reached (5 events).seems like very good results. Let’s see how long it takes the market to ascribe a value to it:

enjoy the weekend all!

cheers,

YS